Meeting
2016 ASCO Annual Meeting
PISARRO: A EUTROC phase 1b study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC).
Authors
Charlie Gourley
University of Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom
Charlie Gourley , John Green , Hani Gabra , Ignace Vergote , Bristi Basu , James D. Brenton , Ulf Björklund , Austin M. Smith , Mikael Von Euler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
2013-001472-38
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5571)
DOI
10.1200/JCO.2016.34.15_suppl.5571
Abstract #
5571
Poster Bd #
394
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC).
First Author: Charlie Gourley
Poster
2011 ASCO Annual Meeting
Phase I safety study of farletuzumab, carboplatin, and pegylated liposomal doxorubicin (PLD) in subjects with platinum-sensitive epithelial ovarian cancer (EOC).
First Author: D. Jelovac
Poster
2020 ASCO Virtual Scientific Program
A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer.
First Author: Susana N. Banerjee
Poster
2016 ASCO Annual Meeting
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
First Author: Steven G. DuBois